MAT1A and metabolic dysfunction-associated steatotic liver disease: The Mat1a-KO mouse model is highly relevant to human liver disease, as MAT1A expression is markedly reduced in most patients with ALD, metabolic dysfunction-associated steatotic liver disease (MASLD), cirrhosis and HCC, and recapitulates the metabolic profile observed in a large subset (~40–50%) of MASLD patients [94].